Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets?
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The ability to use double-stranded RNA to inhibit gene expression sequence-specifically (RNA interference, or RNAi) is currently revolutionizing science and medicine alike. Numerous pre-clinical studies are evaluating RNAi as a novel therapeutic modality in the battle against gain-of-function autosomal dominant diseases, cancer, and viral infections. One emerging concern is that RNAi mono-therapies might ultimately fail to control viruses that can escape silencing by mutation and/or RNAi suppression. Thus, sophisticated strategies are being developed that aim to avert viral resistance by combining RNAi effectors with each other or with further gene expression inhibitors. Several reports already validate this new concept of "combinatorial RNAi" (coRNAi) and illustrate its versatility by describing co-expression of RNAi triggers directed against single or multiple, viral or cellular, targets. Other studies document the successful delivery of these triggers with additional RNA- or protein-based silencers. Moreover, vectors have been engineered to blend RNAi-mediated gene inhibition with conventional gene replacement strategies. Collectively, these efforts open up exciting new therapeutic avenues but could also augment the inherent risks of RNAi technology, including immune responses, off-targeting, and oversaturation of endogenous pathways. Here, we critically review all coRNAi strategies and discuss the requirements for their transition into clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 3×
“16 Although the detailed mechanism of toxicity is still under investigation, in line with our in vivo data, other groups have consistently reported concentration-dependent cytotoxic effects from shRNA overexpression in cultured cells.”
BackgroundResultInfluentialSelf-citationNew microRNAs from mouse and human
LAGOS-QUINTANA, M., RAUHUT, R., MEYER, J., BORKHARDT, A., & TUSCHL, T. (2003) · RNA · doi:10.1261/rna.2146903 · Cited by 909
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection
Palliser, D., Chowdhury, D., Wang, Q.-Y., Lee, S. J., Bronson, R. T., Knipe, D. M., & Lieberman, J. (2006) · Nature · doi:10.1038/nature04263 · Cited by 410 · cited 1×
“11 Notable recently reported siRNA applications include protection of mice against lethal infection with herpes simplex virus-2 13 and treatment of acute respiratory syncytial virus infection (a leading cause of child death).”
Background
Cited by
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
“From a therapeutic standpoint, this could enable more complex therapeutic approaches, where silencing of multiple targets achieve an enhanced therapeutic effect (24).”
BackgroundGeisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
RNA interference against viruses: strike and counterstrike
Haasnoot, J., Westerhout, E. M., & Berkhout, B. (2007) · Nature Biotechnology · doi:10.1038/nbt1369 · Cited by 295
Multifunctional RNA Nanoparticles
Afonin, K. A., Viard, M., Koyfman, A. Y., Martins, A. N., Kasprzak, W. K., Panigaj, M., Desai, R., Santhanam, A., Grabow, W. W., Jaeger, L., et al. (2014) · Nano Letters · doi:10.1021/nl502385k · Cited by 219
Grimm, D., Wang, L., Lee, J. S., Schürmann, N., Gu, S., Börner, K., Storm, T. A., & Kay, M. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43565 · Cited by 196
“Further assets are their small sizes (~95/239 for H1/7SK versus ~500 bp for U6), making them ideal for combined gene silencing/addition strategies employing viral gene therapy vectors (61).”
BackgroundSelf-citation
Metadata
- Authors
- Grimm, D., & Kay, M. A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-05
- Volume
- 15
- Issue
- 5
- Pages
- 878-888
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2047178946
- Cited by
- 137
- References
- 3
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets? https://app.cochat.ai/papers/10.1038/sj.mt.6300116
- The paper
- Grimm, D., & Kay, M. A. (2007). Combinatorial RNAi: A Winning Strategy for the Race Against Evolving Targets? Molecular Therapy. https://doi.org/10.1038/sj.mt.6300116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.